{
"id":"mk19_qq_q068",
"number":68,
"bookId":"qq",
"correctAnswer":"B",
"title":"Question 68",
"stimulus":[
{
"type":"p",
"hlId":"29580c",
"children":[
"A 68-year-old man is hospitalized because of a transient ischemic attack."
]
},
{
"type":"p",
"hlId":"e745dc",
"children":[
"ECG, prolonged telemetry, echocardiography, carotid ultrasonography, and coagulation studies are normal. Head CT shows evidence of a previous stroke."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"182194",
"class":"cell text l",
"children":[
"Total cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6ff723",
"class":"cell text l",
"children":[
"198 mg/dL (5.13 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"0c2f10",
"class":"cell text l",
"children":[
"LDL cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"b88d69",
"class":"cell text l",
"children":[
"100 mg/dL (2.59 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"8a43cb",
"class":"cell text l",
"children":[
"HDL cholesterol"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"4af189",
"class":"cell text l",
"children":[
"38 mg/dL (0.98 mmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"109a07",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Triglycerides",
"children":[
"Triglycerides"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"9c5f63",
"class":"cell text l",
"children":[
"300 mg/dL (7.77 mmol/L)"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"bead78",
"children":[
"Aspirin and clopidogrel are initiated, and lifestyle counseling is ongoing."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"78ff87",
"children":[
"Which of the following is the most appropriate additional treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Atorvastatin plus ezetimibe"
}
},
{
"letter":"B",
"text":{
"__html":"High-intensity rosuvastatin"
}
},
{
"letter":"C",
"text":{
"__html":"Icosapent ethyl"
}
},
{
"letter":"D",
"text":{
"__html":"Moderate-intensity atorvastatin"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"1bd38f",
"children":[
"Secondary prevention of atherosclerotic cardiovascular disease (ASCVD) with high-intensity statin therapy is indicated in all patients who have clinical manifestations ASCVD: acute coronary syndrome, coronary revascularization, stroke or transient ischemic attack, or peripheral artery disease."
]
},
{
"type":"keypoint",
"hlId":"6a557d",
"children":[
"High-intensity statin therapy includes atorvastatin (40-80 mg/d) or rosuvastatin (20-40 mg/d)."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"46d82b",
"children":[
"In addition to antiplatelet therapy and lifestyle counseling, high-intensity statin therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") is indicated. Secondary prevention of atherosclerotic cardiovascular disease (ASCVD) with high-intensity statin therapy is indicated in all patients who have clinical manifestations of ASCVD. Clinical ASCVD comprises acute coronary syndrome, coronary revascularization, stroke or transient ischemic attack, or peripheral artery disease. High-intensity statin therapy includes atorvastatin (40-80 mg/d) or rosuvastatin (20-40 mg/d). Patients should have repeat serum lipid testing performed 4 to 12 weeks after statin initiation to ensure goal LDL reduction of 50% or more. Patients at very high risk for recurrent ASCVD events should have a goal LDL cholesterol level of less than 70 mg/dL."
]
},
{
"type":"p",
"hlId":"c532a1",
"children":[
"Ezetimibe is a second-line cholesterol-lowering agent that can be added to statin therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") for patients at very high risk for ASCVD who have not achieved their LDL goal of less than 70 mg/dL with statin therapy alone. It can also be used in patients with ASCVD who are intolerant of statins despite multiple attempts. Ezetimibe plus a statin may eventually be appropriate therapy if this patient does not reach his LDL cholesterol goal of less than 70 mg/dL but is not an initial therapy."
]
},
{
"type":"p",
"hlId":"b3c4d8",
"children":[
"In patients with persistently elevated triglyceride levels despite statin therapy and either established cardiovascular disease or diabetes mellitus and multiple other risk factors, the addition of icosapent ethyl (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"), a highly purified fish oil, may decrease the risk of cardiovascular events. Icosapent ethyl should not replace high-intensity statin therapy in this high-risk individual, and this patient has no indication for adding icosapent ethyl to statin therapy."
]
},
{
"type":"p",
"hlId":"5d0c98",
"children":[
"According to guidelines, moderate-intensity statin therapy (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is not the first choice for patients with recurrent clinical ASCVD due to the superior benefits of high-intensity statin therapy in this population."
]
}
],
"relatedSection":"mk19_a_gm_s8_2_2_1",
"objective":{
"__html":"Reduce the risk for recurrent atherosclerotic cardiovascular disease events with statin therapy."
},
"references":[
[
"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1046-e1081. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30565953",
"target":"_blank"
},
"children":[
"PMID: 30565953"
]
},
" doi:10.1161/CIR.0000000000000624"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
},
"hlIds":[
"29580c",
"e745dc",
"a462a3",
"182194",
"6ff723",
"0c2f10",
"b88d69",
"8a43cb",
"4af189",
"109a07",
"9c5f63",
"bead78",
"78ff87",
"1bd38f",
"6a557d",
"46d82b",
"c532a1",
"b3c4d8",
"5d0c98"
]
}